ACKR3 and Hepatic fibrosis: Furthermore, the fact that the ACKR3 agonist compound 18a increased the bioavailability of CXCL12 (which can act as an agonist on the CXCR4 receptor) may even have counterbalanced the beneficial effect on liver fibrosis.